Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WPD Pharmaceuticals Inc.: "On May 12, 2020, WPD and Mariusz Olejniczak, WPD’s CEO, filed a petition to terminate the trading suspension. In accordance with Rule of Practice 550(b), additional written submissions are requested."
Accordingly, IT IS ORDERED that the parties file submissions as follows:
By May 21, 2020, the Division of Enforcement shall file all the
information that was before the Commission at the time of the Trading
Suspension Order’s issuance.
By June 4, 2020, petitioners shall file an opening brief, which is not to exceed 8,000 words.
By June 18, 2020, the Division shall file an answering brief, which is
not to exceed 8,000 words.
By July 2, 2020, petitioners may file an optional reply brief, which is not to exceed 3,000 words.
https://www.sec.gov/litigation/opinions/2020/34-88871.pdf
All three are connect in various ways, including board members. The reducing by 100% reduction related to COVID comment was there likely trigger, among others. Murky waters as we're dealing with scientific results, politics, out of field regulators. Should probably write this one off... Too bad, especially for mbrx as they looked promising long term..
$WCOTF: They'll bring it back again ...........
April 8-9 trading made it go haywire.
Company is active.
https://www.globenewswire.com/news-release/2020/04/29/2023924/0/en/WPD-Pharmaceutical-s-Annamycin-Drug-Approved-for-Accelerated-European-Clinical-Trial.html
GO $WCOTF
Only the U.S. OTC stock was suspended and the suspension does not affect the WBIO stock on the Canadian Exchange, unless the CDN's will also think some securities violations occurred.
and now, all three suspended.
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense
agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which
grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor.
That explains a few things...Does anyone know if shareholders have to frame our stock certificate on the wall as a momento or is there a avenue out of this pending results of suspension?
WPD Pharmaceuticals Inc. WCOTF on the OTC SEC Suspension "because of questions regarding the accuracy and adequacy of information in the marketplace about the Company and its securities. Those questions relate to, among other things, statements made by WCOTF and others, in a press release on April 9, and in other statements on March 19, March 20, and April 13, concerning the Company’s business, including the status of development of a drug candidate labeled WP1122 for potential application to COVID-19, and the ability to expedite regulatory approval of any such treatment."
https://www.sec.gov/litigation/suspensions/2020/34-88800.pdf
Order:
https://www.sec.gov/litigation/suspensions/2020/34-88800-o.pdf
Can anyone post a Level II photo for friday after hours? Montage shows 3 bids. Are there more?
WCOTF Slap the ask .75’s
This looks promising...
Not sure how to buy, do you purchase as $$WCOTF symbol?
Without a doubt:) loading the cheapies:)
$WBIO/$WCOTF: Very solid Press Release
This has a very good chance of seeing several dollars again.
GO $WCOTF
$WBIO/$WCOTF: TH2 Patent
https://www.wpdpharmaceuticals.com/_resources/news/Jan%209%202020.pdf
GO $WCOTF
$WBIO/$WCOTF: Total Funding............ $89Million
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer.
Now at $0.71
GO $WCOTF
$WBIO/$WCOTF: Another tweet this morning..........
https://twitter.com/WPDPharma/status/1249685266756964352?s=20
GO $WCOTF
Its a Scam, .71 now Hoped ya took profits @ 10.00 Obviously not LOL GLTY
$WBIO/$WCOTF: Heading back to $4
WP1122............. no one really paying attention about it yet.
CNSP news today........... they'll be turning their attention here.
GO $WCOTF
$WBIO/$WCOTF: Now $0.77............ nice dip opp
GO $WCOTF
$WBIO/$WCOTF: NEWS.... CNSP using WP1122 compound, CoronaVirus
CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals
8:00 AM ET 4/13/20 | PR Newswire
Related Quotes
4:00 PM ET 4/9/20
Symbol Last % Chg
CNSP
3.34 0.00%
Real time quote.
CNS Pharmaceuticals to receive 50% of net sales on resulting anti-viral commercial products, including WP1122, in certain international markets
HOUSTON, April 13, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that independent research by the University of Frankfurt found 2-deoxy-D-glucose ("2-DG") to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.
Researchers at the University of Frankfurt disclosed the findings in their article submitted to NatureResearch on March 11, 2020 (Bojkova, D et al; DOI: 10.21203/rs.3.rs-17218/v1) (https://www.researchsquare.com/article/rs-17218/v1). The authors reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV--2 replication in Caco--2 cells. Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis. 2-DG inhibits glycolysis because, although it appears to cells to be glucose, it is in fact a decoy that cannot be converted into energy.
As previously announced, CNS entered into an agreement with WPD Pharmaceuticals Inc. (CSE: WBIO), for the development of several preclinical drug candidates including WP1122. WP1122, which is being tested on a range of viruses including the coronavirus SARS-CoV-2, is a prodrug of the glucose decoy called 2-deoxy-D-glucose, or 2-DG. While the free form of 2-DG is rapidly metabolized and ineffective within minutes of entering the body, WP1122 has a much longer half-life, potentially enabling it to deliver quantities adequate for a therapeutic effect. WPD Pharmaceuticals previously licensed rights to a portfolio of drug candidates, including WP1122, from Moleculin Biotech, Inc. for certain territories.
"We are extremely encouraged by this breakthrough discovery of WP1122's potential efficacy in fighting COVID-19," commented John M. Climaco, CEO of CNS Pharmaceuticals. "We believe these findings represent a significant catalyst and incentive to expedite the development of WP1122. We look forward to working closely with WPD Pharmaceuticals to continue the advancement of the WP1122 program toward a potential life-saving treatment for this deadly disease, the death toll from which is nearly 100,000 lives worldwide this year and climbing every hour."
Under the CNS Agreement, WPD will receive a portion of the development costs from CNS for WP1122 and other drug candidates for antiviral indications, and CNS will receive certain economic rights. WPD received an upfront cash payment of $225,000 and CNS has committed to a milestone payment of $775,000 upon the successful completion of a Phase 2 study. In return for the funding, CNS is entitled to receive 50% of the net sales, less WPD's license costs, of resulting commercial products in WPD's licensed territories, other than Poland. Those territories include 29 countries in Europe and Asia, including Russia.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is proposed for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as for pancreatic and ovarian cancers, and lymphomas. The Company entered into an intellectual property (IP) agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata. For more information, visit www.cnspharma.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of WPD to develop the drug candidates subject to the development agreement. These statements relate to future events, future expectations, plans and prospects. Although CNS believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may, " "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Risk Factors" in the Form S-1 we filed with the SEC on October 7, 2019. Any forward-looking statements contained in this release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
View original content to download multimedia:www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals-301039193.html
SOURCE CNS Pharmaceuticals, Inc.
/CONTACT: Investor Relations Contact, James Salierno / Kait Brosco, The Ruth Group, 646-536-7028 / 7032, jsalierno@theruthgroup.com, kbrosco@theruthgroup.com, OR Media Contact, Kirsten Thomas, The Ruth Group, (508) 280-6592, kthomas@theruthgroup.com
/Web site: http://www.cnspharma.com
> Dow Jones Newswires
License Partners are:
CNSP - CNS Pharma.(NASDAQ) & MBRX(NASDAQ)
= Licence - Partner of WPD / Read it.
Alpha Pro Tech / APT at (AMEX) / Mega News
at Alpha Pro Tech
( Protect - Mask Producer & Protect Equipment & more)
Also Mega News at IBIO & Inovio
Pending for Mega - News at AKERS
Check it
GLTA Longs
High was 10.00 then it closed @ 1.25 Major Pimp & Dump LOL
$WCOTF: Annamycin Fast track FDA approval
https://www.globenewswire.com/news-release/2020/02/05/1980019/0/en/WPD-Pharmaceuticals-Annamycin-Drug-Received-FDA-Approval-of-Fast-Track-Designation.html
GO $WCOTF
$WCOTF/WBIO: Admin should change this board to $WCOTF
This is the OTC Listing for WPD Pharmaceuticals.
GO $WCOTF
NEWS OUT FROM THE COMPANY CHECK THEIR WEBSITE TO THE MOON !!!!
$WCOTF/WBIO: 33% Insider ownership
https://www.wpdpharmaceuticals.com/_resources/presentations/corporate-presentation.pdf
Now $1.30
GO $WCOTF
$WCOTF/WBIO: Nice report came out on March 23
http://media.stockhouse.com/media/companies/c-wbio/alert/032420-c-wbio-v1.html
Best part of the article...........
GO $WCOTF
$WCOTF/WBIO: Moleculin-BIO FacebookPage talks about $WCOTF's WP1122
https://www.facebook.com/moleculin
GO $WCOTF
Hit $10, traded the $3 range the first 30 minutes.
This is the real deal here! Been posting all AM in the main boards. This is about to pop to $3-5 this afternoon with any burst of volume. Co is working with CNSP and MBRX!
$WCOTF/WBIO: Just TWEETED !!!!!!!!!!!!!!!!!!!!!!!!!!
https://twitter.com/WPDPharma/status/1248290492321689601?s=20
https://twitter.com/WPDPharma/status/1248234708846006273?s=20
GO $WCOTF
$WCOTF/WBIO: This reminds me of how Remdesevir can't work
Without Captisol from Ligand.
Exactly the same kinda predicament.
Nice way for WPD candidate to provide a solution to CoronaVirus via
Moleculin
No wonder the massive interest in it today.
Looks solid... more people will study and learn about it this weekend.
Now at $1.45
GO $WCOTF
$WCOTF/WBIO: Welcome aboard..............
If only Admin could rename this board to $WCOTF
Because that is the Official OTC ticker symbol.
But WBIO is legitimate as well
GO $WCOTF
From Dow Jones newswire: WPD Pharma Research Shows WP1122 Could Reduce Replication of Covid-19 Virus
8:50 am ET April 9, 2020 (Dow Jones) Print
By Chris Wack
WPD Pharmaceuticals Inc. said Thursday that independent research on its WP1122 drug compound found 2-deoxy-D-glucose to reduce replication of SARS-CoV-2, the virus that causes Covid-19, by 100% in in vitro testing.
WPD said it would collaborate with its development partner CNS Pharmaceuticals Inc. to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.
WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech Inc.
"We are excited with this breakthrough on our WP1122 drug candidate and the early implications are that it could have positive effects on reducing the spread of Covid-19," commented Mariusz Olejniczak, chief executive of WPD.
$WCOTF/WBIO: OS 112Million
https://www.wpdpharmaceuticals.com/
GO $WCOTF
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
111
|
Created
|
01/29/20
|
Type
|
Free
|
Moderators |
VANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD in collaboration with its development partner CNS Pharmaceuticals, Inc. (“CNS”)(Nasdaq: CNSP) intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.
WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq: MBRX). Recently, researchers at the University of Frankfurt disclosed the findings in their article submitted to NatureResearch on March 11, 2020 (Bojkova, D et al; DOI: 10.21203/rs.3.rs-17218/v1) (https://www.researchsquare.com/article/rs-17218/v1). The authors reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells. Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis. 2-DG inhibits glycolysis because, although it appears to cells to be glucose, it is in fact a decoy that cannot be converted into energy.
WP1122 is referred to as a “prodrug” of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo. Once administered, these added elements are removed by normal metabolic processes and what remains is 2-DG. As a result, 2-DG is the active compound in WP1122. In chemical terms, it is referred to as the active “moiety” (subpart) of WP1122.
“We are excited with this breakthrough on our WP1122 drug candidate and the early implications are that it could have positive effects on reducing the spread of COVID-19,” commented Mariusz Olejniczak, CEO of WPD. “I would like to commend our license partner, Moleculin and the researchers at the University of Frankfurt for their expedited work and the willingness of the authors to pre-release this data will help support our development of WP1122 for treating COVID-19.”
Walter Klemp, Chairman and CEO of Moleculin added: “This discovery essentially put our development efforts in to turbo-drive. We are moving as quickly as we can to prepare WP1122 for clinical trials. With the US and EU having established accelerated approval procedures for COVID-19 related projects, we expect this to move very quickly. We look forward to WPD’s help, especially as it relates to expediting things in Europe.”
According to WPD’s license partner Moleculin, 2-DG is often referred to as the ‘active moiety’ in WP1122. The issue with 2-DG is that its often metabolized too quickly by the body, so human tissues and organs can’t get enough concentration to be therapeutic. Therefore, even though 2-DG is active against a range of viruses, including SARS-CoV-2, it isn’t useful as a clinical therapy because it metabolizes too rapidly. WP1122 works to solve this problem because it is a ‘prodrug’ of 2-DG. Its structure enables it to achieve much higher tissue/organ concentrations than 2-DG alone, but once it’s in the cell, it metabolizes into the exact same 2-DG that is so effective in vitro.
About WPD Pharmaceuticals
WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes 31 countries in Europe and Asia, including Russia.
On Behalf of the Board
‘Mariusz Olejniczak’
Mariusz Olejniczak
CEO, WDP Pharmaceuticals
Contact:
Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |